Aldeyra Therapeutics (ALDX) Assets Average (2014 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Assets Average came in at $69.3 million in Q1 2026, down 29.96% YoY from $98.9 million in Q1 2025, and down 7.55% on a QoQ basis from $74.9 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Assets Average (2014 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 13 years of Assets Average data on file, last reported at $69.3 million in Q1 2026.
- Quarterly Assets Average fell 29.96% year-over-year to $69.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.3 million (down 29.96% YoY) and the FY2025 annual result came in at $88.3 million, down 30.15% from the prior year.
- Assets Average slipped to $69.3 million in Q1 2026, from $74.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $227.9 million in Q1 2022 to a low of $69.3 million in Q1 2026.
- A 5-year average of $140.1 million and a median of $144.8 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average jumped 97.62% — and 2025, when it slumped 33.36%.
- Tracing ALDX's Assets Average over 5 years: stood at $185.5 million in 2022, then decreased by 20.32% to $147.8 million in 2023, then slipped by 24.93% to $111.0 million in 2024, then plunged by 32.47% to $74.9 million in 2025, then decreased by 7.55% to $69.3 million in 2026.
- The last three Assets Average figures came in at $69.3 million (Q1 2026), $74.9 million (Q4 2025), and $81.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | 57.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.01 Mn |
| Mar 31, 2026 | 69.27 Mn |
| Dec 31, 2025 | 74.93 Mn |
| Sep 30, 2025 | 81.38 Mn |
| Jun 30, 2025 | 89.08 Mn |
| Mar 31, 2025 | 98.90 Mn |
| Dec 31, 2024 | 110.96 Mn |
| Sep 30, 2024 | 121.68 Mn |
| Jun 30, 2024 | 133.67 Mn |
| Mar 31, 2024 | 144.81 Mn |
| Dec 31, 2023 | 147.80 Mn |
| Sep 30, 2023 | 151.45 Mn |
| Jun 30, 2023 | 161.92 Mn |
| Mar 31, 2023 | 174.76 Mn |
| Dec 31, 2022 | 185.49 Mn |
| Sep 30, 2022 | 195.35 Mn |
| Jun 30, 2022 | 211.85 Mn |
| Mar 31, 2022 | 227.92 Mn |
| Dec 31, 2021 | 240.18 Mn |
| Sep 30, 2021 | 251.82 Mn |